Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 14:13:1150777.
doi: 10.3389/fonc.2023.1150777. eCollection 2023.

A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer

Diana V Maslov  1 , Quinne Sember  1 , Jason Cham  2 , Munveer Bhangoo  1
Affiliations
Review

A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer

Diana V Maslov et al. Front Oncol. .

Abstract

Prostate cancer is the most common cancer in men. About 6% of those diagnosed will develop metastatic disease. Unfortunately, metastatic prostate cancer is fatal. Prostate cancer can be castration sensitive or castration resistant. Many treatments have been shown to improve progression free survival and overall survival in metastatic castration resistant prostate cancer (mCRPC). In recent years, studies have been exploring targeting mutations in the DNA Damage Repair (DDR) response that may amplify oncogenes. In this paper, we aim to discuss DDR, new approved targeted therapies, and the most recent clinical trials in the setting of metastatic CRPC.

Keywords: DNA damage (DDR); castration refractory prostate cancer (CRPC); metastatic; prostate cancer; target therapeutics.

PubMed Disclaimer

Conflict of interest statement

JC is supported by the linked award KL2TR002552. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Similar articles

See all similar articles

References

    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin (2014) 64:9–29. doi: 10.3322/caac.21208 - DOI - PubMed
    1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. . Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. (2013) 49:1374–403. doi: 10.1016/j.ejca.2012.12.027 - DOI - PubMed
    1. Rawla P. Epidemiology of prostate cancer. World J Oncol (2019) 10(2): 63–9. doi: 10.14740/wjon1191 - DOI - PMC - PubMed
    1. Zhou Y, Bolton EC, Jones JO. Androgens and androgen receptor signaling in prostate tumorigenesis. J Mol Endocrinol (2015) 54(1):R15–29. doi: 10.1530/JME-14-0203 - DOI - PubMed
    1. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. . Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 18(1):P11–22. doi: 10.1016/j.ccr.2010.05.026 - DOI - PMC - PubMed

LinkOut - more resources